Marnix Bosch
Chief Technical Officer Northwest Biotherapeutics
Seminars
Wednesday 2nd December 2026
DCVax: A Personalized, Multi-Targeted Dendritic Cell Vaccine for Cancer
12:30 pm
- Managing complex and treatment-resistant malignancies requires moving beyond standardized regimens that target only one or a few tumor antigens to an approach that harnesses the patient's own immune system to enable targeting hundreds of tumor antigens
- DCVax is a platform technology and a multi-targeted cancer immunotherapy designed to address the unique antigenic profile of an individual's tumor to elicit broad T-cell responses and greatly expand a patient’s T cell repertoire
- DCVax-L completed a Phase 3 trial that showed the first survival extension over standard of care in many years in both newly-diagnosed and recurrent glioblastoma (GBM) while more than doubling 5-year survival rates
